SMAD4 and neoplasm: In addition, P53 and SMAD4 staining showed a comparable reactivity in most cases (13 out of 16) of PDX-primary tumor pairs (Figure 2B, 2C, 2E, 2F, 2H, and 2I, and Supplementary Figure S3).